サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1159210

好酸球性食道炎治療の世界市場（2022年～2028年）

Eosinophilic Esophagitis Treatment Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 130 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
好酸球性食道炎治療の世界市場（2022年～2028年）
出版日: 2022年09月23日
発行: Orion Market Research
ページ情報: 英文 130 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の好酸球性食道炎治療の市場規模は、予測期間中にCAGRで6.4%の大幅な成長が予測されています。市場は、好酸球性食道炎の償還シナリオの増加や、世界中でのプロトンポンプ阻害剤の使用の拡大などの重大な動向の出現により、予測期間中に目覚ましい成長を示すと考えられています。

当レポートでは、世界の好酸球性食道炎治療市場について調査分析し、市場動向、セグメント分析、地域分析、企業プロファイルなどを提供しています。

目次

第1章 レポートサマリー

第2章 市場の概要と考察

  • 調査範囲
  • アナリストの考察と現在の市場動向

第3章 競合情勢

  • 主要企業の分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の発展
  • 主な戦略の分析
  • 主要企業に対するCOVID-19の影響

第4章 市場セグメンテーション

  • 世界の好酸球性食道炎治療市場：製品別
    • ブデソニド経口懸濁液
    • フルチカゾンODT
    • メポリズマブ
    • レスリズマブ
    • ベンラリズマブ
    • その他
  • 世界の好酸球性食道炎治療市場：診断別
    • 上部内視鏡検査
    • 食道生検
    • 血液検査
  • 世界の好酸球性食道炎治療市場：治療法別
    • 食事療法
    • 投薬
    • 拡張

第5章 地域の分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • その他の地域

第6章 企業プロファイル

  • Adare Pharmaceuticals, Inc.
  • Allakos, Inc.
  • Astrazeneca
  • Axcan Pharma, Inc.
  • Bristol-Myers Squibb
  • Celgene Corp.
  • Ception Therapeutics Inc.
  • Dr. Falk Pharma Gmbh
  • DBV Technologies
  • Hikma Pharmaceuticals Plc
  • Novartis AG
  • Perrigo Co. Plc
  • Regeneron Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
  • 2. GLOBAL BUDESONIDE ORAL SUSPENSION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL FLUTICASONE ODT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL MEPOLIZUMAB MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL RESLIZUMAB MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL BENRALIZUMAB MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL OTHERS PRODUCT FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 9. GLOBAL UPPER ENDOSCOPY FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL ESOPHAGUS BIOPSY FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL BLOOD TESTS FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 13. GLOBAL DIETARY THERAPY FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL MEDICATION FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL DILATION FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 17. NORTH AMERICAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
  • 19. NORTH AMERICAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 21. EUROPEAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. EUROPEAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
  • 23. EUROPEAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 24. EUROPEAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 25. ASIA-PACIFIC EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 26. ASIA-PACIFIC EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
  • 27. ASIA-PACIFIC EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 29. REST OF WORLD EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
  • 30. REST OF WORLD EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 31. REST OF WORLD EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET, 2022-2028 (%)
  • 4. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY PRODUCT, 2021VS 2028 (%)
  • 5. GLOBAL BUDESONIDE ORAL SUSPENSION MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 6. GLOBAL FLUTICASONE ODT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 7. GLOBAL MEPOLIZUMAB MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 8. GLOBAL RESLIZUMAB MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 9. GLOBAL BENRALIZUMAB MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 10. GLOBAL OTHERS PRODUCT FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 11. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY DIAGNOSIS, 2021VS 2028 (%)
  • 12. GLOBAL UPPER ENDOSCOPY FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 13. GLOBAL ESOPHAGUS BIOPSY FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 14. GLOBAL BLOOD TESTS FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 15. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY TREATMENT, 2021VS 2028 (%)
  • 16. GLOBAL DIETARY THERAPY FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 17. GLOBAL MEDICATION FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 18. GLOBAL DILATION FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 19. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
  • 20. US EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. CANADA EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. UK EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. FRANCE EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. GERMANY EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. ITALY EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SPAIN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF EUROPE EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. INDIA EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. CHINA EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. JAPAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 31. SOUTH KOREA EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLD EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026287

Global Eosinophilic Esophagitis Treatment Market Size, Share & Trends Analysis Report By Product (Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, and Others), By Diagnosis (Upper Endoscopy, Esophagus Biopsy, and Blood Tests), and By Treatment (Dietary Therapy, Medication, and Dilation) Forecast, 2022-2028

The global eosinophilic esophagitis treatment market is anticipated to grow at a substantial CAGR of 6.4% during the forecast period. The market is set to display impressive growth during the forecast period with some key trends emerging, such as the increased reimbursement scenario in eosinophilic esophagitis along with the growing usage of proton pump inhibitors across the globe. Additionally, increasing awareness programs for eosinophil-associated disorders is also estimated to be the prime factor affecting and impacting the growth of the market.

The global eosinophilic esophagitis treatment market had been positively affected during the COVID-19 pandemic as most of the economic activities were halted during Q1 and Q2 2020. The temporary shutdown of every manufacturing unit had adversely impacted, the growth of the market. However, a various initiative taken by government across the globe is improving market growth.

The global eosinophilic esophagitis treatment market is segmented based on product, diagnosis, and treatment. By product, the market is segmented into budesonide oral suspension, fluticasone ODT, mepolizumab, reslizumab, benralizumab, and others. Further, based on the diagnosis segment, the market is segmented into upper endoscopy, esophagus biopsy, and blood tests. Based on the treatment segment, the market is divided into dietary therapy, medication, and dilation.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is having a significant share in the market for eosinophilic esophagitis treatment. Improving and increasing awareness regarding eosinophilic esophagitis which was once a stronghold of the US and a few European economies such as France, Italy, and Germany is set to expand in emerging economies. The increasing healthcare developments among the population in the Asian economies of Japan, South Korea, Taiwan, and China, which involve the highest degree of innovations, is set to increase the demand for the eosinophilic esophagitis treatment market.

The prominent players functioning in the global eosinophilic esophagitis treatment market include AstraZeneca, Bristol-Myers Squibb, Dr Falk Pharma, Novartis AG, Regeneron Pharmaceuticals, Inc., and Teva Pharmaceuticals Industries Ltd. among others. These key manufacturers are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships, and collaborations, and many others to thrive in a competitive environment. For instance, in October 2018, one of the companies named Dr Falk Pharma had introduced across the UK its Jorveza which is considered as the first globally licensed drug approved for eosinophilic esophagitis.

Research Methodology

The market study of the global eosinophilic esophagitis treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Eosinophilic Esophagitis Treatment Market Research And Analysis By Product

2. Global Eosinophilic Esophagitis Treatment Market Research And Analysis By Diagnosis

3. Global Eosinophilic Esophagitis Treatment Market Research And Analysis By Treatment

The Report Covers:

  • Comprehensive Research Methodology of the global eosinophilic esophagitis treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global eosinophilic esophagitis treatment market.
  • Insights about market determinants that are stimulating the global eosinophilic esophagitis treatment market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Eosinophilic Esophagitis Treatment Market by Product
    • 4.1.1. Budesonide Oral Suspension
    • 4.1.2. Fluticasone ODT
    • 4.1.3. Mepolizumab
    • 4.1.4. Reslizumab
    • 4.1.5. Benralizumab
    • 4.1.6. Others
  • 4.2. Global Eosinophilic Esophagitis Treatment Market by Diagnosis
    • 4.2.1. Upper Endoscopy
    • 4.2.2. Esophagus Biopsy
    • 4.2.3. Blood Tests
  • 4.3. Global Eosinophilic Esophagitis Treatment Market by Treatment
    • 4.3.1. Dietary Therapy
    • 4.3.2. Medication
    • 4.3.3. Dilation

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Adare Pharmaceuticals, Inc.
  • 6.2. Allakos, Inc.
  • 6.3. Astrazeneca
  • 6.4. Axcan Pharma, Inc.
  • 6.5. Bristol-Myers Squibb
  • 6.6. Celgene Corp.
  • 6.7. Ception Therapeutics Inc.
  • 6.8. Dr. Falk Pharma Gmbh
  • 6.9. DBV Technologies
  • 6.10. Hikma Pharmaceuticals Plc
  • 6.11. Novartis AG
  • 6.12. Perrigo Co. Plc
  • 6.13. Regeneron Pharmaceuticals, Inc.
  • 6.14. Sun Pharmaceutical Industries Ltd.
  • 6.15. Teva Pharmaceuticals Industries Ltd.